Orchid Pharma registers turnover of Rs 879 crore in FY16
Chennai, India | May 27, 2016
Financial highlights for year ended March 31, 2016 (FY16) - Standalone
Revenue of Rs 879 crore [US$ 131.7 million] registered during the year ended March 31, 2016 (FY 15-16) as compared to Rs 1753 crore [US$ 262.6 million] registered during the corresponding year ended March 31, 2015 [18 months].
Earnings before Interest, Depreciation and Tax (EBIDTA) stood at Rs 198 crore [US$ 29.8 million] for the fiscal under review compared to Rs 362 crore [US$ 54.2 million] registered during FY 13-15 (18 months).
Net (Loss) for the fiscal ended March 31, 2016 stood at Rs (274) crore [US$ (41.1) million] compared to a loss of Rs (191) crore [US$ (28.6) million] during FY 2013-15 (18 months).
EPS for the fiscal ended March 31, 2016 stood at Rs. (31.51)
* 1 US$ = Rs 66.77
From the Managing Director
“Despite the interruption caused by the torrential rains during the first week of December 2015, the impact of which affected the performance in January and part of February 2016, we are back on track and look forward to the launch of prime non-antibiotics products in the FY 2016-17. With the support of the bankers, our customers and by launching of new products, including products in the first-to-file category, we are confident of improving the volumes and profitability” said Mr K Raghavendra Rao, Managing Director, Orchid Pharma Ltd.